2 completed, 1 enrolling by invitation, 1 recruiting, 1 withdrawn. 3 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow esreboxetine: new trials by email Literature Review of esreboxetine trials Research Report on esreboxetine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia AXS-14 (esreboxetine) - Fibromyalgia | Phase 3 | Enrolling by invitation | Axsome Therapeutics, Inc. | 300 | 2026-04-29 | 2026-11-06 |
| Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design AXS-14 (Esreboxetine), Placebo - Fibromyalgia | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 620 | 2026-01-14 | 2026-11-10 |
| Maintenance of Efficacy. Esreboxetine, Placebo - Fibromyalgia | Phase 3 | Withdrawn | Pfizer | 2009-05-01 | 2018-11-29 | |
| Phase 1 Thorough QT (TQT) Study in Young Healthy Volunteers esreboxetine, placebo, moxifloxacin - Fibromyalgia | Phase 1 | Completed | Pfizer | 40 | 2008-12-01 | 2011-04-07 |
| A Study To Assess Esreboxetine's Effect On Concentration, Memory, Decision Making And Problem Solving In Patients With Fibromyalgia. Esreboxetine - Fibromyalgia | Phase 2 | Completed | Pfizer | 89 | 2008-08-01 | 2018-12-04 |
Fibromyalgia (5) · Hyperalgesia (2)
Pfizer (3) · Axsome Therapeutics, Inc. (2)
United States (3) · Belgium (1)
2008 (1)